electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Company’s product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Company’s TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.
BörsenkürzelECOR
Name des UnternehmenselectroCore, Inc.
IPO-datumJun 22, 2018
CEOMr. Daniel S. Goldberger
Anzahl der mitarbeiter73
WertpapierartOrdinary Share
GeschäftsjahresendeJun 22
Addresse200 Forge Way
StadtROCKAWAY
BörseLondon Stock Exchange
LandUnited States of America
Postleitzahl07866
Telefon19732900097
Websitehttps://www.electrocore.com/
BörsenkürzelECOR
IPO-datumJun 22, 2018
CEOMr. Daniel S. Goldberger
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten